A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

NCT06503679 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: LY4100511 (DC-853) Dose 1
DRUG: LY4100511 (DC-853) Dose 2
DRUG: LY4100511 (DC-853) Dose 3
DRUG: Midazolam
DRUG: Repaglinide
DRUG: Digoxin
DRUG: Rosuvastatin

Sponsor

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company